electroCore Inc ECOR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ECOR is a good fit for your portfolio.
News
-
electroCore Announces the Launch of Truvaga Plus® for General Wellness
-
electroCore Expands Intellectual Property Portfolio
-
electroCore Announces Fourth Quarter and Full Year 2023 Financial Results
-
electroCore to Participate in Upcoming Investor Conferences
-
electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024
-
electroCore Expands Intellectual Property Portfolio
Trading Information
- Previous Close Price
- $5.58
- Day Range
- $5.58–5.58
- 52-Week Range
- $3.83–7.90
- Bid/Ask
- $5.56 / $5.89
- Market Cap
- $33.49 Mil
- Volume/Avg
- 305 / 9,811
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.92
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 62
- Website
- https://www.electrocore.com
Valuation
|
Metric
|
ECOR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.50 |
Price/Sales | 1.92 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ECOR
|
|---|---|
Quick Ratio | 1.36 |
Current Ratio | 1.76 |
Interest Coverage | — |
Quick Ratio
ECOR
Profitability
|
Metric
|
ECOR
|
|---|---|
Return on Assets (Normalized) | −91.74% |
Return on Equity (Normalized) | −157.42% |
Return on Invested Capital (Normalized) | −152.10% |
Return on Assets
ECOR
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Bgrjchjp | Rxmmfm | $185.5 Bil | |
SYK
| Stryker Corp | Nvjxbfsncl | Qtkdf | $128.2 Bil | |
MDT
| Medtronic PLC | Jdzbylj | Nrtfyw | $106.7 Bil | |
BSX
| Boston Scientific Corp | Bcbydywc | Bcclww | $99.0 Bil | |
DXCM
| DexCom Inc | Fzxlfctg | Rrtt | $53.1 Bil | |
EW
| Edwards Lifesciences Corp | Xtjdcvvhw | Spqhc | $52.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Hdffbprzv | Nhnkq | $24.9 Bil | |
ALGN
| Align Technology Inc | Rljjgpk | Myhxbl | $23.5 Bil | |
PHG
| Koninklijke Philips NV ADR | Vzjsxzm | Nwrxf | $18.9 Bil | |
PODD
| Insulet Corp | Kdssyhclfb | Qghjpwb | $11.7 Bil |